



# The Benefits of Early Intervention in AD: More Than Skin Deep

## FACULTY



**Eric Simpson,  
MD, MSCR**  
Oregon Health and  
Science University  
Portland, Oregon  
USA



**Lawrence F.  
Eichenfield, MD**  
University of California  
and  
Rady Children's Hospital  
San Diego, California  
USA



**Katrina Abuabara,  
MD, MA, MSCE**  
University of California  
San Francisco  
San Francisco, California  
USA

## ADVENT at AAD 2024

March 9, 2024 / 7:00–9:00 PM PT / San Diego, CA, USA

## PURPOSE

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

## LEARNING OBJECTIVES

- Present new data on the systemic burden of underlying type 2 inflammation in AD within and beyond the skin across age groups
- Discuss the cumulative life impact of uncontrolled AD and the importance of early intervention and disease control across age groups
- Relate perspectives on management of moderate-to-severe AD and the potential for disease modification

## AGENDA

Welcome, Introductions, Objectives	Eric Simpson
New Data on Systemic Burden of AD in Children and the Need for Early Intervention	Lawrence Eichenfield
Panel Discussion	All
Importance of Achieving Disease Control in Adults with Moderate-to-Severe AD	Eric Simpson
Panel Discussion	All
New Data on Systemic Non-Atopic Comorbidities Across Ages and Practical Considerations in Older Patients with AD	Katrina Abuabara
Panel Discussion	All
Perspectives on the Management of Patients with Moderate-to-Severe AD Across Age Groups	All
Summary and Conclusions	Eric Simpson
Panel Discussion and Live Q&A	All



Explore ADVENT! Award-winning medical education developed with clinical experts to advance the understanding of type 2 inflammation

**Disclaimers:**  
Speakers will receive compensation for their participation in this event. This is a disease state awareness symposium. Speakers will not discuss specific treatments.